World Heath Organization – A
September 2017 report released by WHO shows a serious lack of new
antibiotics under development to combat the growing threat of
antimicrobial resistance. It seems that most of the drugs currently
in the clinical pipeline are modifications of existing classes of
antibiotics and are only short-term solutions. The report found very
few potential treatment options for those antibiotic-resistant
infections identified by WHO as posing the greatest threat to health,
including drug-resistant tuberculosis which kills around 250,000
people each year.
"Antimicrobial resistance is a
global health emergency that will seriously jeopardize progress in
modern medicine," says Dr Tedros Adhanom Ghebreyesus,
Director-General of WHO. "There is an urgent need for more
investment in research and development for antibiotic-resistant
infections including TB, otherwise we will be forced back to a time
when people feared common infections and risked their lives from
minor surgery."
The report went on to conclude that
there is a serious lack of treatment options for multi-drug and
extensively drug-resistant M. tuberculosis and gram-negative
pathogens, including Acinetobacter and Enterobacteriaceae
(such as Klebsiella and E.coli) which can cause severe
and often deadly infections that pose a particular threat in
hospitals and nursing homes....
See Antibacterial agents in clinical development.
See Antibacterial agents in clinical development.
No comments:
Post a Comment